Apraglutide — Hyped or Proven?

What Apraglutide is

Apraglutide is an investigational long-acting GLP-2 analog being studied in intestinal-failure contexts.

Apraglutide is grouped under Approved / Clinical / Fat Loss + GLP-1s on PeptideFactCheck because it matters as part of the real peptide-drug pipeline in gut biology rather than hype-only peptide culture.

The useful starting point is to separate the molecule itself from the internet story around it. It matters as part of the real peptide-drug pipeline in gut biology rather than hype-only peptide culture.

Why people keep looking it up

It matters as part of the real peptide-drug pipeline in gut biology rather than hype-only peptide culture.

Apraglutide is an investigational long-acting GLP-2 analog being studied in intestinal-failure contexts.

Apraglutide tends to stay in the conversation because it touches a familiar public theme: glp-2 analog, intestinal adaptation, and gut support. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Meaningful human development-stage evidence without approval-level status.

Human clinical-stage evidence exists, but this remains investigational rather than approved.

Mechanism follows GLP-2 intestinal-growth and absorptive-support biology.

Why this page carries the current tier: Meaningful human development-stage evidence without approval-level status.

The current seed trail for Apraglutide is pulling from 1 literature source, 1 trials source, and 1 databases source.

Safety, limits, and regulatory context

Clinical-stage gut peptides still need outcome and label clarity before broad claims.

Apraglutide remains investigational in this seed set.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Apraglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for Apraglutide is CID 155559189. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID: 155559189
Formula: C172H263N43O52
Molecular weight: 3765
InChIKey: AVYLMJODKHVQHD-WFOXQDBGSA-N

Matched synonyms include FE 203799, RefChem:558429, CHEMBL4563522, EX-A8460.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for Apraglutide returns 9 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.NCT04699032 | COMPLETED | PHASE1VectivBio AG | first posted 2021-01-07Open trial Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.NCT05018286 | ACTIVE_NOT_RECRUITING | PHASE3VectivBio AG | first posted 2021-08-24Open trial A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic FunctionNCT05706623 | COMPLETED | PHASE1VectivBio AG | first posted 2023-01-31Open trial Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)NCT05415410 | TERMINATED | PHASE2VectivBio AG | first posted 2022-06-13Open trial Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasNCT03417765 | WITHDRAWN | PHASE1, PHASE2GlyPharma Therapeutics | first posted 2018-01-31Open trial

Literature snapshot

The current PubMed query for Apraglutide returns 30 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

How to manage a high-output stoma.Frontline gastroenterology | 2022Nightingale JMD | DOI 10.1136/flgastro-2018-101108Open citation Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum.JPEN. Journal of parenteral and enteral nutrition | 2019 SepSlim GM, Lansing M, Wizzard P, Nation PN | DOI 10.1002/jpen.1500Open citation Efficacy and safety of apraglutide in short bowel syndrome with intestinal failure and colon-in-continuity: A multicenter, open-label, metabolic balance study.Clinical nutrition (Edinburgh, Scotland) | 2024 DecVerbiest A, Hvistendahl MK, Bolognani F, Li C | DOI 10.1016/j.clnu.2024.10.011Open citation Efficacy and safety of glucagon-like peptide 2 in patients with short bowel syndrome: a systematic review and network meta-analysis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract | 2024 JulSabra HK, Remeih GS, Kereet IM, Hamad M | DOI 10.1016/j.gassur.2024.04.009Open citation Use of glucagon-like polypeptide 2 analogs for intestinal failure.Expert opinion on pharmacotherapy | 2024 DecGoldschmidt ML, Oliveira S, Slaughter C, Kocoshis SA | DOI 10.1080/14656566.2024.2431291Open citation

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

PubMed literature searchCitationUsed here to check published human studies, reviews, and preclinical literature.Open source ClinicalTrials.gov searchTrialUsed here to check whether the peptide or related intervention shows up in registered clinical studies.Open source PubChem searchDatabaseUsed here for reference identifiers, structures, sequences, and pharmacology metadata.Open source

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.